Android app on Google Play

Salix Pharmaceuticals Ltd (SLXP) Tops Q4 EPS by 2c

February 28, 2013 4:36 PM EST Send to a Friend
Salix Pharmaceuticals Ltd (NASDAQ: SLXP) reported Q4 EPS of $0.81, $0.02 better than the analyst estimate of $0.79. Revenue for the quarter came in at $198.2 million versus the consensus estimate of $199.41 million.

For earnings history and earnings-related data on Salix Pharmaceuticals Ltd (SLXP) click here.




You May Also Be Interested In


Related Categories

Earnings

Related Entities

Earnings

Add Your Comment